BORTEM-17 preliminary results at European Association for Neuro-Oncology September 25-26, 2021
Main content
We will be presenting our preliminary results from the Phase II clinical trial, (BORTEM-17 ClinicalTrials.gov Identifier: NCT03643549) at this year´s EANO conference. We will also present results characterizing the control group of patients, among which, the comparator for BORTEM-17 patients. Both presentations (Abstract no. P14.09 and P14.65) will be presented on Sunday 26th September from 14:00-14:45 CEST (Central European Summer Time).
It is a great honor for us to participate in this large and important "flagship" conference for brain tumor research and treatment with results from our own intervention trial on a subset of glioblastoma patients with dismal expected survival. This study is a result of basic / translational cancer research from the laboratory bench to the clinic. We are grateful to the Norwegian Cancer Society who made this possible for us.
Program:
https://www.eano.eu/fileadmin/content/EANO_Meetings/EANO_2021/2021_EANO_FinalProgramme_web.pdf
Abstract library: https://www.abstractsonline.com/pp8/#!/10370